FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AJANTPHARM

1,648.1
+18.9 (1.16%)
Updated 03:29 03/08 IST

AJANTPHARM Buy or Sell - FrontPage Forums

1 Users have submitted 1 trade ideas of Rs. 167,350 for AJANTPHARM
Disclaimer
100% Bullish
0% Bearish

AJANTPHARM Buy or Sell - Brokerage Reports

No. of reports in last year
2
No. of analysts
1
Average Consensus Forecast
1545
Consensus Potential
-5.99%
See AJANTPHARM Share Price Targets >>

AJANTPHARM Ratings

Long term AJANTPHARM rating by FrontPage users
3/5 (1 Ratings)
Find answers to all your questions on live AJANTPHARM message board: Is AJANTPHARM buy or sell? Should I buy AJANTPHARM shares? Why are AJANTPHARM shares falling? Should I invest in AJANTPHARM stock?

  1. Home
  2. AJANTPHARM Forum

AJANTPHARM Share Price Discussion

N
Reputation: 4,625 • Today 6:13 AM
Buy Ajanta Pharmaceuticals; target of Rs 1810: ICICI Direct
ICICI Direct is bullish on Ajanta Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1810 in its research report dated July 31, 2020.
Moneycontrol
Like
Reply

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹1,655  ₹1,653.1
Price@Trade
₹1,653
Target Price
₹1,536.1
Stop Price
₹1,714.45
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹99,186 approx for 60 Qty
Status
Active
Like
Reply (5)
Latest replies

Update
Entry Price Modified
Price @ Update
₹1,654.05
Original Entry Price
₹1,655
New Entry Price
₹1,654.05

Update
Entry Price Modified
Price @ Update
₹1,655.95
Original Entry Price
₹1,654.05
New Entry Price
₹1,655.95

Update
Entry Price Modified
Price @ Update
₹1,653.05
Original Entry Price
₹1,655.95
New Entry Price
₹1,653.05

Update
Entry Price Modified
Price @ Update
₹1,653.1
Original Entry Price
₹1,653.05
New Entry Price
₹1,653.1
TrackerBot @trackerbot
Today 6:09 AM

Update
Trade Entered
Entry Price
₹1,653.1
E
Reputation: 152 • Today 4:12 AM

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹1,673.5
Price@Trade
₹1,673.5
Target Price
₹1,750
Stop Price
₹1,600
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹167,350 approx for 100 Qty
Status
Active
Like
Reply
N
Reputation: 4,625 • Today 3:56 AM
Share market update: 56 stocks hit 52-week highs on NSE
Overall, 16 shares were trading in green in Nifty50 index, while 34 were trading in red.
The Economic Times
Like
Reply

Type
Sell
Instrument
AJANTPHARM
Entry Price
₹1,678.55
Price@Trade
₹1,678.55
Target Price
₹1,559.05
Stop Price
₹1,723.9
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹99,034.45 approx for 59 Qty
Status
Active
Like
Reply
K
Reputation: 12,468 • Today 3:52 AM

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹1,672.55
Price@Trade
₹1,672.55
Target Price
₹1,800
Stop Price
₹1,640
Valid Till
Sep 3, 2020 3:20 AM
Margin
₹836,275 approx for 500 Qty
Status
Stoploss Hit
Exit Price
₹1,640
Net P&L
-₹16,275 (-1.95%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Today 6:02 AM

Update
Stoploss Hit
Exit Price
₹1,640
N
Reputation: 4,625 • Today 3:43 AM
Market may consolidate in August: Experts pick 10 stocks that can give 10-30% return
The rollover in Nifty is at 77.59 percent, which is in line with its 3-month average of 77.40 percent, whereas rollover in Bank Nifty is at 75.30 percent compared to the average of 79 percent.
Moneycontrol
Like
Reply
B
Reputation: -1,866 • Today 2:46 AM

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹1,683
Price@Trade
₹1,700.4
Target Price
₹1,730
Stop Price
₹1,650  ₹1,712
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹841,500 approx for 500 Qty
Status
Stoploss Hit
Exit Price
₹1,712
Net P&L
+₹14,500 (+1.72%)
Like
Reply (3)
Latest replies
TrackerBot @trackerbot
Today 2:47 AM

Update
Trade Entered
Entry Price
₹1,683
babul @soumen-BJkPbopcU
Today 2:48 AM

Update
Stoploss Trailed
Price @ Update
₹1,713.15
Original SL
₹1,650
New SL
₹1,712
TrackerBot @trackerbot
Today 2:49 AM

Update
Stoploss Hit
Exit Price
₹1,712
N
Reputation: 4,625 • Yesterday 1:28 AM
DAILY VOICE: Nifty to trade with mild weakness in August series; rally in IT stocks may pause
The rally in the IT stocks may take a pause, however, the pharma index has just closed above the 61.8% Fibonacci retracement level of the previous major decline indicating room for an extended rally on cards.
Moneycontrol
Like
Reply

STRONG BREAKOUT DONE WITH STRONG VOLUME....
BREAK HURDLE 1540---1550
NEXT UPSIDE TARGET SEEN...
1680----1850---2000+++++
Like
Reply

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹1,612
Price@Trade
₹1,609
Target Price
₹1,850
Stop Price
₹1,400
Valid Till
Aug 31, 2020 3:20 AM
Margin
₹80,600 approx for 50 Qty
Status
Exited
Exit Price
₹1,690.75
Net P&L
+₹3,937.5 (+4.89%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 31 8:05 AM

Update
Trade Entered
Entry Price
₹1,612

Update
Exited
Exit Price
₹1,690.75
Net P&L
+₹3,937.5 (+4.89%)
Trading & Education in AJANTPHARM
INTRADAY + POSITIONAL - BUY AJANTPHARM 1510 TGT...
Like
Reply
N
Reputation: 4,625 • Jul 31 3:23 AM
Ajanta Pharma Standalone June 2020 Net Sales at Rs 560.85 crore, up 2.77% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 31 3:23 AM
Ajanta Pharma Consolidated June 2020 Net Sales at Rs 668.20 crore, up 9.19% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 10:13 AM
Ajanta Pharma Q1 profit up 29% at Rs 148 crore
Total export sales in the quarter were at Rs 483 crore as against Rs 404 crore in the year-ago period, registering a growth of 19 per cent, the company said.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 9:51 AM
Ajanta Pharma Q1 results: Profit up 29% at Rs 148 crore
Ajanta Pharma on Thursday reported 28.90 per cent rise in consolidated net profit to Rs 147.76 crore for the quarter ended June 30, 2020.
The Economic Times
Like
Reply

INTRADAY + POSITIONAL - BUY AJANTPHARM 1510 TGT 1550 1600 1650 SL PAID #AJANTPHARM
Like
Reply
N
Reputation: 4,625 • Jul 28 7:43 AM
Market up 48% from March lows; time to change strategy and rejig portfolio?
The recent rally has brought many stocks near their peak valuation, Investors can relook at their portfolio and bring down the equity portion if it has exceeded the intended allocation, say experts.
Moneycontrol
Like
Reply
B
Reputation: 11,014 • Jul 22 3:03 AM

Type
Buy
Instrument
AJANTPHARM
Entry Price
₹1,447.5
Price@Trade
₹1,449.7
Target Price
₹1,469
Stop Price
₹1,429
Valid Till
Jul 22, 2020 3:20 AM
Margin
₹723,750 approx for 500 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Baddshaah @baddshaah
Jul 22 3:13 AM

Update
Exited before entry
Price @ Update
₹1,457
N
Reputation: 4,625 • Jul 20 3:43 AM
Short-term bets: 10 trading ideas that can return 7-20% as Nifty climbs 11K
The upmove should ideally get extended towards the 78.6% retracement zone at 11100 – 11200. From here on, one step at a time is the strategy to follow and better to timely book profits as well in the rally.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AJANTPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization9,036.61
    Enterprise Value9,000.74
    Price to Earnings29.08
    Price to Book Value4.22
    Return on Capital Employed0.29
    Return on Equity0.22
    Face Value2
    Dividend YieldNA
  • AJANTPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    27-Feb-20Motilal OswalBuy1,655
    6-Feb-20Motilal OswalBuy1,435
    1-Aug-19ICICIdirect.comHold1,010
    2-Feb-19Reliance SecuritiesBuy1,225
    1-Feb-19ICICIdirect.comBuy1,100
    AJANTPHARM Brokerage Price Target
  • AJANTPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 31670172516301647.4
    Jul 31151716481490.051629.2
    Jul 301509153814551512.4
    Jul 2914501509.91445.11489.3
    Jul 2814761486.7514351443.2
  • AJANTPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,459.71
    30 Day Moving Average₹1,452.7
    50 Day Moving Average₹1,459.33
    100 Day Moving Average₹1,410.69
    200 Day Moving Average₹1,248.67
  • AJANTPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,830.451,822.710
    Operating Profit546.81636.01-0.14
    Profit Before Tax562.44640.65-0.12
    Net Income427.52499.81-0.14
  • AJANTPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1431,931.50.11
    Total Liabilities379381.35-0.01
    Total Assets2,5222,312.850.09
  • AJANTPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity219.16529.06-0.59
    Cash from Investing Activity-201.12-349.66-0.42
    Cash from Financing Activity-0.54-194.08-1
    Net Cash Flow17.5-14.68-2.19
  • AJANTPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.180.29
    Return on Equity0.220.33
    Return on Capital Employed0.290.43
  • AJANTPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.35
    3 Year CAGR Growth in Operating Profit0.17
    3 Year CAGR Growth in EBIDTA0.24
    3 Year CAGR Growth in Net Income0.4
    3 Yr CAGR Growth - Diluted EPS0.39
  • AJANTPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.18
    5 Year CAGR Growth in Operating Profit1.64
    5 Year CAGR Growth in EBIDTA1.89
    5 Year CAGR Growth in Net Income3.23
    3 Yr CAGR Growth - Diluted EPS0.12
  • AJANTPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Today 6:13 AM
    Buy Ajanta Pharmaceuticals; target of Rs 1810: ICICI Direct
    Moneycontrol
    NewsBot
    Today 3:56 AM
    Share market update: 56 stocks hit 52-week highs on NSE
    The Economic Times
    NewsBot
    Today 3:43 AM
    Market may consolidate in August: Experts pick 10 stocks that can give 10-30% return
    Moneycontrol
    NewsBot
    Yesterday 1:28 AM
    DAILY VOICE: Nifty to trade with mild weakness in August series; rally in IT stocks may pause
    Moneycontrol
    NewsBot
    Jul 31 3:23 AM
    Ajanta Pharma Standalone June 2020 Net Sales at Rs 560.85 crore, up 2.77% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 31 3:23 AM
    Ajanta Pharma Consolidated June 2020 Net Sales at Rs 668.20 crore, up 9.19% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 30 10:13 AM
    Ajanta Pharma Q1 profit up 29% at Rs 148 crore
    Moneycontrol
    NewsBot
    Jul 30 9:51 AM
    Ajanta Pharma Q1 results: Profit up 29% at Rs 148 crore
    The Economic Times
    NewsBot
    Jul 28 7:43 AM
    Market up 48% from March lows; time to change strategy and rejig portfolio?
    Moneycontrol
    NewsBot
    Jul 20 3:43 AM
    Short-term bets: 10 trading ideas that can return 7-20% as Nifty climbs 11K
    Moneycontrol
  • AJANTPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • AJANTPHARM - More Information

    keyboard_arrow_down

    Ajanta Pharma Limited:
    Ajanta Pharma Limited is among the nation’s most prestigious pharmaceutical company, announcing their mission to serve the global healthcare with empathy, innovation and technology. The firm was established in the year of 1973 with headquarter at Mumbai. The company is announcing to ‘Serve Healthcare Needs Worldwide’. The company is aiming to use cutting edge technology to bring innovations.
    The company is developing its business internationally to achieve their aim. The company is currently pursuing its business in India, USA and around thirty other countries in Asia, Africa, CIS and the Middle East. With a Research and Development team enriched with more than 750 scientists, Ajanta Pharma is possessing a workforce of more than 7,500 employees all over the world. The company has currently 1,400 products in different countries around the globe with a deep focus on the market of USA, expecting a good outcome. Ajanta Pharma has been manufacturing anti-malarial products for the health programmes in Africa approved by WHO.
    Company Information:
    Soon after its inception in 1973, Ajanta Pharma Limited has been pursuing tremendous achievements in its journey towards the golden jubilee. In 1979, the company produced branded ‘Over The Counter’ products along with developing its first manufacturing facility set-up at Chikalthana, India. By seven years the firm set up its second manufacturing facility at Paithan, India. By 1989, Ajanta Pharma reached a milestone of manufacturing more than 30 ‘Over The Counter’ products. The company intervened the international market for the first time in 1992. In 1995 the company developed its subsidiary at Mauritius with a manufacturing facility set-up. Millennium brought a credible achievement for the company while Ajanta Pharma had been enlisted in National Stock Exchange and Bombay Stock Exchange. The company intervened the domestic prescription market in 2002, introducing speciality segment force.
    As the company has been in the process of in traducing innovations, it developed its R&D facility at Kandivli. Establishing an Active Pharmaceutical Ingredient (API) Plant at Waluj in Aurangabad, the company got the approval of USFDA in 2007. In the same year, Ajanta Pharma developed a manufacturing facility in Aurangabad for rapid growth. The company received its international recognition in the same year by becoming the world’s first generic company to achieve WHO Geneva Pre-qualification for Anti-Malarial Drug. In 2010, Ajanta Pharma intervened the market of the Philippines through Ajanta Philippines Inc. Ophthalmology, Dermatology, Cardiology— these are the three segments where the company created its reign and emerged in the leading position in 2011.
    In the next year, the company achieved its place among the top ten pharmaceutical companies in Franco Africa. The company started its journey to explore the USA market in the year 2013. Ajanta Pharma inaugurated its Research & Development centre at Kandivli, Mumbai to expand its innovations and after that the business in a larger periphery. Inauguration of a new facility was done in Dahej, 2015 to fulfil the requirements of the USA market and WHO. Montelukas Sodium Oral Granules were announced to launch by Ajanta in 2015 along with the announcement of the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in the US market. In the year 2017, the company developed its new facility in Guwahati. In the same year, USFDA has approved Ajanta Pharma’s Dahej facility.
    The company is currently spending 9% of its revenue in Research & Development in the financial year of 2019-20. From 28 different nationalities, the company has appointed more than 7500 people as its permanent staff. The total income in the fiscal year of 2019-20 is 2076 crore INR; the company has been enjoying a net profit of 387 crore INR in the same financial year. The current EBITDA margin of the company in the current fiscal year of 2019-20 is 28%.
    The company is announcing its philosophy as first to create opportunities and then optimize them on fullest.
    How Ajanta Pharma Ltd, is categorised as Pharmaceuticals and Health Care Sector, and Pharmaceuticals Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Ajanta Pharma Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Ajanta Pharma Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020